Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ding Wu

Showing results (171-180 of 172) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 172 results.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|April 3, 2004
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]Zhong-zhen Guan, Dong-geng Liu, Bao-ming Yu, et al.
Molecular Cancer|November 22, 2025
Targeting SERPINB3-MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapyXiao-Xiao Huang, Cheng-Ke Xie, Yi-Chao Mo, et al.
Pageof 18

Showing results (171-180 of 172) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 172 results.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|April 3, 2004
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]Zhong-zhen Guan, Dong-geng Liu, Bao-ming Yu, et al.
Molecular Cancer|November 22, 2025
Targeting SERPINB3-MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapyXiao-Xiao Huang, Cheng-Ke Xie, Yi-Chao Mo, et al.
Pageof 18